Gain-of-function R225W mutation in human AMPKγ3 causing increased glycogen and decreased triglyceride in skeletal muscle

PLoS ONE

Volumn 2, Issue 9, 2007, Pages

  Costford, Sheila R ^a   Kavaslar, Nihan ^b   Ahituv, Nadav ^d   Chaudhry, Shehla N ^a   Schackwitz, Wendy S ^d,e   Dent, Robert ^c   Pennacchio, Len A ^d   McPherson, Ruth ^b   Harper, Mary Ellen ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^e DOE JOINT GENOME INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; TRIACYLGLYCEROL; PRIMER DNA;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DENSITOMETRY; ENERGY BALANCE; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; EXON; FEMALE; GENE MUTATION; GENETIC CONSERVATION; GENETIC VARIABILITY; GLYCOGEN MUSCLE LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MUSCLE BIOPSY; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PHYSICAL ACTIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SATELLITE CELL; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SKELETAL MUSCLE; SPECIES DIFFERENCE; SWINE; TISSUE SPECIFICITY; VASTUS LATERALIS MUSCLE; WESTERN BLOTTING; WOLFF PARKINSON WHITE SYNDROME; GENETICS; METABOLISM; MUTATION; PEDIGREE;

ANIMALIA; MAMMALIA; SUIDAE;

AMP-ACTIVATED PROTEIN KINASES; BASE SEQUENCE; BLOTTING, WESTERN; DNA PRIMERS; FEMALE; GLYCOGEN; HUMANS; MALE; MUSCLE, SKELETAL; MUTATION; PEDIGREE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIGLYCERIDES;

EID: 41249096989     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000903     Document Type: Article

References (41)

1. Hamilton SR, Stapleton D, O'Donnell JB Jr, Kung JT, Dalal SR, et al. (2001) An activating mutation in the gamma1 subunit of the AMP-activated protein kinase. FEBS Lett 500: 163-168.
2. Burwinkel B, Scott JW, Buhrer C, van Landeghern FK, Cox GF, et al. (2005) Fatal congenital heart glycogenosis caused by a recurrent activating R531Q, mutation in the gamma 2-subunit of AMP-activatcd protein kinase (PRKAG2), not by phosphorylase kinase deficiency Am J Hum Genet 76: 1034-1049.
3. Scott JW, Hawley SA, Green KA, Anis M, Stewart G, et al. (2004) CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin Invest 113: 274-284.
4. Hardie DG, Carling, D (1997) The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur J Biochem 246: 259-273.
5. Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25.
6. Hardie DG, Sakamoto K (2006) AMPK: a key sensor of fuel and energy status in skeletal muscle. Physiology (Bethesda) 21: 48-60.
7. Barnes BR, Marklund S, Steiler TL, Walter M, Hjalm, G, et al. (2004) The 5′- AMP-activated protein kinase gamma3 isoform has a key role in carbohydrate and lipid metabolism in glycolytic skeletal muscle. J Biol Chem 279: 38441-38447.
8. Bergeron R, Previs SF, Cline GW, Perret P, Russell RR 3rd, et al. (2001) Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 50: 1076-1082.
9. Buhl ES, Jessen N, Pold R, Ledet T, Flyvbjerg A, et al. (2002) Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 51: 2199-2206.
10. Buhl ES, Jessen N, Schmitz O, Pedersen SB, Pedersen O, et al. (2001) Chronic treatment with 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in rat skeletal muscles in a fiber type-specific manner. Diabetes 50: 12-17.
11. Winder WW, Hardie DG (1999) AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 277: E1-10.
12. Carling D (2004) The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 29: 18-24.
13. Crute BE, Seefeld K, Gamble J, Kemp BE, Witters LA (1998) Functional domains of the alpha1 catalytic subunit of the AMP-activated protein kinase. J Biol Chem 273: 35347-35354.
14. Mahlapuu M, Johansson C, Lindgren K, Hjalm G, Barnes BR, et al. (2004) Expression profiling of the gamma-subunit isoforms of AMP-activated protein kinase suggests a major role for gamma3 in white skeletal muscle. Am J Physiol Endocrinol Metab 286: E194-200.
15. Wojtaszewski JF, Birk JB, Frosig C, Holten M, Pilegaard H, et al. (2005) 5′ AMP activated protein kinase expression in human skeletal muscle: effects of strength training and type 2 diabetes. J Physiol 564: 563-573.
16. Frosig C, Jorgensen SB, Hardie DG, Richter EA, Wojtaszewski JF (2004) 5′-AMP-activated protein kinase activity and protein expression are regulated by endurance training in human skeletal muscle. Am J Physiol Endocrinol Metab 286: E411-417.
17. Nielsen JN, Mustard EJ, Graham DA, Yu H, MacDonald CS, et al. (2003) 5′-AMP-activated protein kinase activity and subunit expression in exercise-trained human skeletal muscle. J Appl Physiol 94: 631-641.
18. Birk JB, Wojtaszewski JF (2006) Predominant alpha2/beta2/gamma3 AMPK activation during exercise in human skeletal muscle. J Physiol 577: 1021-1032.
19. Cheung PC, Salt IP, Davies SP, Hardie DG, Carling D (2000) Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J 346 Pt 3: 659-669.
20. Lang T, Yu L, Tu Q, Jiang J, Chen Z, et al. (2000) Molecular cloning, genomic, organization, and mapping of PRKAG2, a heart abundant gamma2 subunit of 5′-AMP-activated protein kinase, to human chromosome 7q36. Genomics 70: 258-263.
21. Gollob MH, Seger JJ, Gollob TN, Tapscott T, Gonzales O, et al. (2001) Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitadon and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation 104: 3030-3033.
22. Dyck JRB, Lopaschuk GD (2006) AMPK alterations in cardiac physiology and pathology: enemy or Ally? J Physiol (Lond):. pp jphysiol.2006.109389.
23. Daniel T, Carling D (2002) Functional analysis of mutations in the gamma 2 subunit of AMP-activated protein kinase associated with cardiac hypertrophy and Wolff-Parkinson-White syndrome. J Biol Chem 277: 51017-51024.
24. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, et al. (2001) Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 344: 1823-1831.
25. Arad M, Benson DW, Perez-Atayde AR, McKenna WJ, Sparks EA, et al. (2002) Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 109: 357-362.
26. Milan D, Jeon JT, Looft C, Amarger V, Robic A, et al. (2000) A mutation in PRKAG3 associated with excess glycogen content in pig skeletal muscle. Science 288: 1248-1251.
27. Ahituv N, Kavaslar N,, Schackwitz W, Ustaszewska A, Martin J, et al. (2007) Medical sequencing at the extremes of human body mass. Am J Hum Genet 80: 779-791.
28. Ahituv N, Kavaslar N, Schackwitz W, Ustaszewska A, Collier JM, et al. (2006) A PYY Q62P variant linked to human obesity. Hum Mol Genet 15: 387-391.
29. Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30: 3894-3900.
30. Ng PC, Henikoff S (2002) Accounting for human polymorphisins predicted to affect protein function. Genome Res 12: 436-446.
31. Ingham KC (1990) Precipitation of proteins with polyethylene glycol. Methods Enzymol 182: 301-306.
32. Hardie DG, Salt IP, Davies SP (2000) Analysis of the role of the AMP-activated protein kinase in the response to cellular stress. Methods Mol Biol 99: 63-74.
33. Davies SP, Carling D, Hardie DG (1989) Tissue distribution of die AMP-activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay. Eur J Biochem 186: 125-128.
34. Andersson L (2003) Identification and characterization of AMPK gamma 3 mutations in the pig. Biochem Soc Trans 31: 232-235.
35. Hedegaard J, Horn P, Lametsch R, Sondergaard Moller H, Roepstorff P, et al. (2004) UDP-glucose pyrophosphorylase is upregulated in carriers of the porcine RN- mutation in the AMP-activated protein kinase. Proteomics 4: 2448-2454.
36. Yu H, Hirshman MF, Fujii N, Pomerleau JM, Peter LE, et al. (2006) Musclespecific overexpression of wild type and R225Q mutant AMP-activated protein kinase gamma3-subunit differentially regulates glycogen accumulation. Am J Physiol Endocrinol Metab 291: E557-565.
37. Fujii N, Jessen N, Goodyear LJ (2006) AMP-activated protein kinase and the regulation of glucose transport. Am J Physiol Endocrinol Metab 291: E867-877.
38. Barnes BR, Long YC, Steiler TL, Leng Y, Galuska D, et al. (2005) Changes in Exercise-Induced Gene Expression in 5′-AMP-Activatcd Protein Kinase {gamma}3-Null and {gamma}3 R225Q Transgenic Mice. Diabetes 54: 3484-3489.
39. Zhou G, Myers R, Li Y, Chen Y, Shen Y, et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174.
40. Fryer LG, Parbu-Patel A, Carling D (2002) The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277: 25226-25232.
41. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, et al. (2002) Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51: 2074-2081.